Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4

Texto completo
Autor(es):
Mostrar menos -
Pinheiro, Celine [1, 2] ; Miranda-Goncalves, Vera [3, 4] ; Longatto-Filho, Adhemar [3, 2, 4, 5] ; Vicente, Anna L. S. A. [2] ; Berardinelli, Gustavo N. [2] ; Scapulatempo-Neto, Cristovam [6] ; Costa, Ricardo F. A. [1] ; Viana, Cristiano R. [6] ; Reis, Rui M. [3, 2, 4] ; Baltazar, Fatima [4, 3] ; Vazquez, Vinicius L. [2, 7]
Número total de Autores: 11
Afiliação do(s) autor(es):
[1] Dr Paulo Prata FACISB, Barretos Sch Hlth Sci, Sao Paulo - Brazil
[2] Barretos Canc Hosp, Mol Oncol Res Ctr, Sao Paulo - Brazil
[3] ICVS 3Bs PT Govt Associate Lab, Braga - Portugal
[4] Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Hlth Sci, Braga - Portugal
[5] Univ Sao Paulo, Sch Med, Lab Med Invest LIM 14, Sao Paulo - Brazil
[6] Barretos Canc Hosp, Dept Pathol, Sao Paulo - Brazil
[7] Barretos Canc Hosp, Dept Surg, Melanoma Sarcoma, Sao Paulo - Brazil
Número total de Afiliações: 7
Tipo de documento: Artigo Científico
Fonte: CELL CYCLE; v. 15, n. 11, p. 1462-1470, 2016.
Citações Web of Science: 14
Resumo

BRAF mutations are known drivers of melanoma development and, recently, were also described as players in the Warburg effect, while this reprogramming of energy metabolism has been identified as a possible strategy for treating melanoma patients. Therefore, the aim of this work was to evaluate the expression and prognostic value of a panel of glycolytic metabolism-related proteins in a series of melanomas. The immunohistochemical expression of MCT1, MCT4, GLUT1, and CAIX was evaluated in 356 patients presenting melanoma and 20 patients presenting benign nevi. Samples included 20 benign nevi, 282 primary melanomas, 117 lymph node and 54 distant metastases samples. BRAF mutation was observed in 29/92 (31.5%) melanoma patients and 17/20 (85%) benign nevi samples. NRAS mutation was observed in 4/36 (11.1%) melanoma patients and 1/19 (5.3%) benign nevi samples. MCT4 and GLUT1 expression was significantly increased in metastatic samples, and MCT1, MCT4 and GLUT1 were significantly associated with poor prognostic variables. Importantly, MCT1 and MCT4 were associated with shorter overall survival. In conclusion, the present study brings new insights on metabolic aspects of melanoma, paving the way for the development of new-targeted therapies. (AU)

Processo FAPESP: 12/04194-1 - Avaliação do papel biológico e clínico de alterações nas vias moleculares RAS-MAPK e PI3K-Akt , em melanomas cutâneos e de mucosa em população brasileira e comparação com a população estadunidense
Beneficiário:Vinicius de Lima Vazquez
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 15/25351-6 - O MCT1 como alvo terapêutico e mediador de resposta no tratamento de melanomas
Beneficiário:Céline Marques Pinheiro
Linha de fomento: Auxílio à Pesquisa - Apoio a Jovens Pesquisadores